Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2025

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Show Description +

Dr. Chan explores the risk of diabetic retinopathy and other complications between patients with type 2 diabetes and obesity treated with bariatric surgery and patients taking GLP-1 receptor agonists.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

bariatric surgery

•

obesity

•

Diabetes

•

Diabetic Retinopathy

•

GLP-1

•

receptor agonist

•

complications

Up Next

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Phase 2 Data on Gene Therapy for AMD

Phase 2 Data on Gene Therapy for AMD

Christine Kay, MD

OCS-01 (Oculis) in DME: A Phase 3 Update

OCS-01 (Oculis) in DME: A Phase 3 Update

Carl Danzig, MD

Gene Therapy for Wet AMD: New Phase 2 Data

Gene Therapy for Wet AMD: New Phase 2 Data

Dante Pieramici MD

Surgical Pearls for Sickle Cell Retinopathy

Surgical Pearls for Sickle Cell Retinopathy

Jennifer I. Lim, MD

Dosing Considerations with 8 mg Aflibercept

Dosing Considerations with 8 mg Aflibercept

Mark R. Barakat, MD

Pegcetacoplan in the Real World: Year 1

Pegcetacoplan in the Real World: Year 1

Mengxi Shen, MD, PhD

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Back to All Videos

Bariatric Surgery Versus GLP-1 Receptor Agonists

Christabel Chan, MD

Dr. Chan explores the risk of diabetic retinopathy and other complications between patients with type 2 diabetes and obesity treated with bariatric surgery and patients taking GLP-1 receptor agonists.

Posted: 5/16/2025

Keywords:

retina-meeting-recap

•

bariatric surgery

•

obesity

•

Diabetes

•

Diabetic Retinopathy

•

GLP-1

•

receptor agonist

•

complications

Please log in to leave a comment.

More From ARVO: 2025 Coverage

Phase 2a Data Revealed for AVD-104 (Aviceda)

Phase 2a Data Revealed for AVD-104 (Aviceda)

Baruch D. Kuppermann, MD, PhD

Real-World Data for 8 mg Aflibercept

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

$The Benefits of Refractive Vitrectomy for SVOs$

The Benefits of Refractive Vitrectomy for SVOs

Paulo Eduardo Stanga, MD

Treating DR with Axitinib

Treating DR with Axitinib

Neal S. Shah, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2025.